GLOBEFLEX CAPITAL L P - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 409 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.

Quarter-by-quarter ownership
GLOBEFLEX CAPITAL L P ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$1,665,467
+57.6%
31,808
+22.4%
0.17%
+68.9%
Q1 2024$1,056,866
+10.1%
25,9800.0%0.10%
+5.1%
Q4 2023$960,221
-3.2%
25,9800.0%0.10%
-15.5%
Q3 2023$992,436
+19.7%
25,980
+13.1%
0.12%
+26.1%
Q2 2023$828,889
-5.6%
22,9800.0%0.09%
-14.0%
Q1 2023$877,606
-32.9%
22,9800.0%0.11%
-35.5%
Q4 2022$1,307,562
-12.8%
22,980
-39.4%
0.17%
-35.7%
Q3 2022$1,499,000
-15.5%
37,905
-6.0%
0.26%
-40.4%
Q2 2022$1,774,000
-18.8%
40,323
-26.4%
0.43%
-2.3%
Q1 2022$2,185,000
-50.4%
54,789
-50.0%
0.44%
-1.8%
Q4 2021$4,404,000
+3977.8%
109,530
+4044.2%
0.45%
+1779.2%
Q3 2021$108,000
-78.2%
2,643
-85.7%
0.02%
-81.0%
Q2 2020$496,000
-43.8%
18,495
-79.3%
0.13%
-42.7%
Q4 2016$883,000
-18.2%
89,3880.0%0.22%
-18.5%
Q3 2016$1,080,000
+40.1%
89,3880.0%0.27%
+28.0%
Q2 2016$771,000
-36.1%
89,388
-29.8%
0.21%
-34.7%
Q1 2016$1,206,000
+1006.4%
127,388
+1922.0%
0.32%
+1013.8%
Q4 2015$109,000
-84.0%
6,300
-87.6%
0.03%
-80.1%
Q3 2015$681,000
-43.3%
50,700
-4.7%
0.15%
-33.6%
Q2 2015$1,201,00053,2000.22%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2023
NameSharesValueWeighting ↓
Third Security, LLC 14,092,771$206,177,00028.12%
BB BIOTECH AG 8,322,860$121,763,0003.90%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 398,633$4,579,0002.84%
DOHENY ASSET MANAGEMENT /CA 227,193$3,324,0002.43%
SNYDER CAPITAL MANAGEMENT L P 2,833,759$41,458,0002.24%
First Light Asset Management, LLC 938,399$13,729,0002.19%
IRIDIAN ASSET MANAGEMENT LLC/CT 9,027,164$132,067,0001.77%
Taylor Wealth Management Partners 204,277$2,989,0001.72%
Sterling Global Strategies LLC 22,000$321,860,0001.63%
Granite Investment Partners, LLC 988,939$14,468,0001.06%
View complete list of HALOZYME THERAPEUTICS INC shareholders